RXST

INSIDER SELL

RxSight, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)

5.5d↑+2.6%

as of 2026-09-15

News Summary

Negative

RxSight reported Q2 2026 revenue of $33.7M (including $6.5M from new Alcon collaboration), but underlying product sales declined 18.7% year-over-year in the first half of 2026, prompting a leadership transition and full-year guidance withdrawal. The company faces margin pressure from higher inventory costs and softer adoption trends, with analyst downgrades to 'Sell' and consensus price targets around $8 reflecting diminished near-term prospects.

Red flags

•H1 2026 product sales down 18.7% YoY ($58.1M vs. prior year $71.5M)
•CEO departure and leadership transition (July 2026) signaling instability
•Full-year 2026 guidance withdrawn pending strategic review
•Gross margin pressure: excluding Alcon, Q2 margin fell to 71.2% from 74.9% YoY
•Multiple analyst downgrades (Morgan Stanley to Equalweight, Wall Street Zen to Sell)
•Consensus price target ~$8 reflecting reduced investor confidence

Insider Activity

Name	Title	Type	Shares	Price	Value	Filed	Src
Kurtz Ronald M MD	Chief Medical Officer	SELL	5K	$6.96	$0.04M	2026-09-02	↗
Wilterding Mark	Chief Financial Officer	SELL	8K	$6.96	$0.05M	2026-09-02	↗
Goldshleger Ilya	Chief Operating Officer	SELL	2K	$6.96	$0.01M	2026-09-02	↗
Weinberg Eric	See remarks	SELL	2K	$6.96	$0.01M	2026-09-02	↗

Fund 13D/13G Filings (1)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

Fund	Form	∆ Shares	% of Class	Since Filing	Filed	Src
Point72	SC 13G	NEW	6.0%	-23.7% vs SPY -22.7% abs	2026-08-19	↗